Pasha Romanovski
Founding Partner @ Hanaco Venture Capital
Tel Aviv, Israel
Pasha Romanovski is a seed investor at Hanaco Venture Capital in Tel Aviv focused on Artificial Intelligence and Health Care. Pasha Romanovski is the Founding Partner of Hanaco Venture Capital. He previously worked at Socialist as a Founder and Managing Partner. Pasha Romanovski attended Alliance Manchester Business School.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 52%
Last updated:
For AI agents: llms.txt
Industries Pasha Romanovski invests in
Artificial IntelligenceHealth CareMachine LearningMedicalTraining
Stages Pasha Romanovski invests in
SeedSeries ASeries CSeries BSeries D
Countries Pasha Romanovski invests in
IsraelGermanyUnited States
Investment Focus
Industry
- Artificial Intelligence 4 (15%)
- Health Care 3 (11%)
- Machine Learning 3 (11%)
- Medical 2 (7%)
- Training 2 (7%)
Stage
- Seed 5 (19%)
- Series A 5 (19%)
- Series C 4 (15%)
- Series B 3 (11%)
- Series D 2 (7%)
Country
- Israel 10 (37%)
- Germany 1 (4%)
- United States 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SpotitEarly
|
SpotitEarly offers a pre-screening test for various cancers using a single breath sample. This innovative approach allows individuals to conduct cancer screenings conveniently at home. The test accurately identifies four major cancer types: Breast, Lung, Colon, and Prostate. By simplifying the detection process, SpotitEarly aims to enhance earlydiagnosis, which is crucial for effective treatment. The company focuses on making cancer detection accessible and non-invasive, catering to the needs of patients and healthcare providers alike. Through its unique method, SpotitEarly contributes to advancing health management and early intervention strategies. | $20.3M / May 17, 2025 | |
SeeTree
|
SeeTree offers you complete transparency into the health and production of each of your trees by leveraging the most powerful innovations available. | $17.5M / Series C / Jan 17, 2024 | |
Chain Reaction
|
Chain Reaction is engineering the future of disruptive blockchain and privacy technologies. They accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems.EL3CTRUM is their Blockchain product line, starting with the most efficient hashing ASIC on the market, optimized forhigh-performance, high efficiency, and low-power, and is the heart of their hashboards and systems. EL3CTRUM delivers optimal payback time.3PU™ is their Privacy product, dramatically accelerating real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, and enabling new verticals to adopt the cloud at scale, including financial institutions, healthcare & big pharma, defense & government, oil & gas, and more. Purpose-built and custom-designed, their solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet. | $70M / Series C / Feb 23, 2023 | |
|
Chain Reaction
|
Chain Reaction is engineering the future of disruptive blockchain and privacy technologies. They accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems.EL3CTRUM is their Blockchain product line, starting with the most efficient hashing ASIC on the market, optimized forhigh-performance, high efficiency, and low-power, and is the heart of their hashboards and systems. EL3CTRUM delivers optimal payback time.3PU™ is their Privacy product, dramatically accelerating real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, and enabling new verticals to adopt the cloud at scale, including financial institutions, healthcare & big pharma, defense & government, oil & gas, and more. Purpose-built and custom-designed, their solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet. | $70M / Series C / Feb 23, 2023 | |
MDI Health
|
MDI Health offers an AI-powered platform that provides unique decision support tools for personalized drug treatments. It uses its patent-pending technology, methodology, and algorithms to ensure early detection of potential Medication-Related Problems (MRPs) during the course of the drug treatment and to ensure the optimal balance between efficacyand safety of the treatment. | $20M / Series A / Feb 13, 2023 | |
Vesttoo
|
Vesttoo is the world’s first marketplace for non-catastrophe insurance-based risk transfer and investments. Our proprietary AI-based technology facilitates risk transfer between insurance companies and institutional investors, providing insurance-linked investments to asset managers of all types, while enhancing risk transfer and liquidity in theLife and P&C insurance markets.Our platform facilitates risk transfer to the capital markets with a faster time to market, providing insurers with an affordable, accurate alternative or supplement to traditional reinsurance with unlimited capacity from the capital markets, while we offer asset managers a variety of risk remote, uncorrelated investment options that generate sustainable alpha from a catered variety of insurance and reinsurance premiums.We collaborate with leaders in the field to build alternative reinsurance transactions covering a variety of Life and P&C insurance risks in transparent, data-driven alternative reinsurance and retrocession deals - run-off or treaty, parametric or portfolio-specific, standalone or on top of existing reinsurance towers. Our proprietary AI-based Machine Learning models have been developed independently, accepted by regulators, and externally audited by leaders in the field. Vesttoo was selected to participate in IBM Alpha Zone, Citigroup Accelerator, Plug and Play and Fintech Innovation Lab – all prestigious fintech accelerators, and most recently NVIDIA's inception program. Our management team has a diversified professional experience in global business development, investments, technology/systems/algorithms, financial engineering, reinsurance, credit rating and managementAdditional team members include: data scientists, financial engineers, actuaries, product managers, project managers, business development, strategy and marketing professionals. | $80M / Series C / Oct 25, 2022 | |
|
SpotitEarly
|
SpotitEarly offers a pre-screening test for various cancers using a single breath sample. This innovative approach allows individuals to conduct cancer screenings conveniently at home. The test accurately identifies four major cancer types: Breast, Lung, Colon, and Prostate. By simplifying the detection process, SpotitEarly aims to enhance earlydiagnosis, which is crucial for effective treatment. The company focuses on making cancer detection accessible and non-invasive, catering to the needs of patients and healthcare providers alike. Through its unique method, SpotitEarly contributes to advancing health management and early intervention strategies. | $6.2M / Seed / Jun 23, 2022 | |
|
SpotitEarly
|
SpotitEarly offers a pre-screening test for various cancers using a single breath sample. This innovative approach allows individuals to conduct cancer screenings conveniently at home. The test accurately identifies four major cancer types: Breast, Lung, Colon, and Prostate. By simplifying the detection process, SpotitEarly aims to enhance earlydiagnosis, which is crucial for effective treatment. The company focuses on making cancer detection accessible and non-invasive, catering to the needs of patients and healthcare providers alike. Through its unique method, SpotitEarly contributes to advancing health management and early intervention strategies. | $6.2M / Seed / Jun 23, 2022 | |
|
Chain Reaction
|
Chain Reaction is engineering the future of disruptive blockchain and privacy technologies. They accelerate compute performance, enabling companies to adopt and scale solutions to the world’s most complex problems.EL3CTRUM is their Blockchain product line, starting with the most efficient hashing ASIC on the market, optimized forhigh-performance, high efficiency, and low-power, and is the heart of their hashboards and systems. EL3CTRUM delivers optimal payback time.3PU™ is their Privacy product, dramatically accelerating real-time operations of Privacy Enhancing Technologies on encrypted data, transforming the cloud into a trusted environment, and enabling new verticals to adopt the cloud at scale, including financial institutions, healthcare & big pharma, defense & government, oil & gas, and more. Purpose-built and custom-designed, their solutions power the next generation of secure, scalable, green computing to help protect people, privacy, and the planet. | $70M / Series C / May 01, 2022 | |
Redefine Meat
|
Redefine Meat uses 3D printing technology, meat digital modeling, and food formulations to produce animal-free meat. Redefine Meat technology produces animal-free meat with the same appearance, texture, and flavor of animal meat, from natural and sustainable ingredients. It was founded in 2018 and headquartered in Tel Aviv, Israel. | $135M / Venture - Series Unknown / Jan 23, 2022 | |
| See all 27 investments → | |||
Co-Investors
fresh.fund
4 deals together
Atomico
3 deals together
Atreides Management
3 deals together
BlueRun Ventures
3 deals together
CPT Capital
3 deals together
Greycroft
3 deals together
About Hanaco Venture Capital
Hanaco Venture Capital is a technology company with visionary and passionate entrepreneurs. Hanaco was founded by Alon Lifshitz, Lior Prosor, and Pasha Romanovski in 2017 and is headquartered in Tel Aviv, Israel.
Hanaco Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alon Lifshitz
Founding Partner
|
|||
Lior Prosor
Founding Partner
|
|||
|
Pasha Romanovski
Founding Partner
|
|||
Allison Stoloff
Senior Associate
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Medical Investors
18,848 investors
EdTech Investors
18,221 investors
Machine Learning Investors
17,935 investors
SaaS VC Funds
61,208 investors
Health Care VC Funds
32,370 investors
Artificial intelligence VC Funds
27,398 investors
FAQ
What does Pasha Romanovski invest in?
Pasha Romanovski invests primarily in Artificial Intelligence, Health Care and Machine Learning startups, most often at Seed and Series A stage. Most of the 27 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Pasha Romanovski last invest?
The most recent investment recorded for Pasha Romanovski closed in May 2025. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
